Answers are grounded in this paper and cite their sources.
INTRODUCTION: Molecular profiling increasingly guides genitourinary cancer management, but biomarker maturity and clinical utility vary across prostate, urothelial, renal, and testicular cancers. AREAS COVERED: This review examines homologous recombination repair (HRR) and germline testing, PARP inhibition, and PSMA theranostics in prostate cancer; FGFR3-targeted therapy and circulating tumor DNA (ctDNA)-guided adjuvant immunotherapy in urothelial carcinoma; predictive biomarker limitations and HIF-2α-directed therapy in renal cell carcinoma; and investigational serum miR-371a-3p in testicular cancer. PubMed/MEDLINE was searched from January 2016 through October 2026, supplemented by conference proceedings and clinical guidelines. EXPERT OPINION: Germline testing informs treatment selection and hereditary-risk assessment in prostate cancer, but remains selective in urothelial and renal cancers, primarily for hereditary-risk assessment, with syndrome-directed therapy in von Hippel-Lindau disease. It has no established role in testicular cancer. Molecular profiling currently guides management in prostate and urothelial cancers. In renal cancer, PD-L1 and tumor mutational burden remain non-predictive, while transcriptomic signatures are investigational. In testicular cancer, miR-371a-3p outperforms conventional serum markers diagnostically but cannot detect teratoma, and its clinical utility remains unvalidated.
No takes yet. Share an insight, caveat, or question.
Collins et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: